跳转至内容
Merck
CN
  • NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.

NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.

The Lancet. Oncology (2013-05-28)
Matthew Dyer, Joanna Richardson, Janet Robertson, Jane Adam